Protein Transporter: Biologics with a
Biologic Transporter

The PT Platform allows for the oral delivery of biologics that otherwise would break down in the digestive system through an active, naturally occurring endocytosis process.

ProgramDiscoveryPre-ClinicalPhase 1
Oral Delivery
Platform
PT-1 EPO
Discovery
Pre-Clinical
Phase 1
PT-2 Octreotide
Discovery
Pre-Clinical
Phase 1
PT-3 GLP-1 Agonist
Discovery
Pre-Clinical
Phase 1
Key
2021-2022
2022-2023

Naturally Occurring Oral Delivery

Through an active endocytosis process, a biologic drug fused with Imagine Pharma’s PT System is absorbed into the apical cell wall, travels and exits through the basal wall where the transporter is naturally cleaved off delivering the cargo into the blood stream.

RESEARCH & DEVELOPMENT ENGINE

Powering New Discovery

The foundation of the three platforms forms the basis of a multi-year scientific inquiry which will lead to many discoveries and potential therapies to increase the number of patients that can benefit from our transformative first-in-class treatments. With research programs targeting areas where there are currently no treatments and current approaches are not cost effective or have failed, Imagine is pushing the boundaries of what is possible.

We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.

R & D EngineDiscoveryPre-ClinicalPhase 1
2nd Generation Oral Delivery System
Discovery
Pre-Clinical
Phase 1
Additional Oral Biologics
Discovery
Pre-Clinical
Phase 1
Comprehensive Lung Healing Initiative
Discovery
Pre-Clinical
Phase 1
Comprehensive Bowel Initiative
Discovery
Pre-Clinical
Phase 1
Personalized Blood
Vessel
Discovery
Pre-Clinical
Phase 1